Roivant Executive and Leadership Team

Matthew Gline, the Chief Executive Officer at Roivant, directs the company's overarching strategy and operational execution. Gline guides Roivant's mission to complete the development of promising late-stage drug candidates and deliver innovative healthcare technologies. Overseeing all business units, the Chief Executive Officer ensures alignment with the company's tech-enabled approach to healthcare. This leadership role involves fostering innovation and driving the efficient delivery of novel treatments to patients worldwide. By integrating advanced technologies with clinical development, Matthew Gline directly impacts Roivant's ability to address unmet medical needs and enhance patient access to groundbreaking therapies. Ultimately, Gline secures the company's long-term growth and market leadership in the biopharmaceutical sector.

Eric Venker, the President at Roivant, drives the strategic execution of the company's business development and operational initiatives. Venker focuses on advancing Roivant's mission to complete late-stage drug development and introduce innovative healthcare technologies. Leading cross-functional teams, the President ensures seamless collaboration between research, development, and commercialization efforts. This position involves identifying and capitalizing on opportunities to enhance patient access to critical medicines. By fostering strategic partnerships and optimizing resource allocation, Eric Venker directly supports Roivant's growth trajectory and its commitment to improving global health outcomes. Ultimately, Venker solidifies the company's operational framework, enabling the efficient delivery of life-changing therapies.

Ian Rosenblum, the Chief Information Officer at Roivant, architects the company's digital infrastructure and information technology strategy. Rosenblum spearheads the integration of advanced technologies across Roivant's operations, supporting the development and delivery of innovative healthcare solutions. Overseeing all IT departments, the Chief Information Officer ensures robust data security, system efficiency, and seamless technological integration for drug candidate development. This critical role involves leveraging data analytics and digital platforms to accelerate clinical trials and enhance patient engagement. By optimizing technological resources, Ian Rosenblum directly contributes to Roivant's tech-enabled healthcare model, enabling faster progress in bringing novel treatments to market. Ultimately, Rosenblum strengthens the company's operational backbone, facilitating innovation and global reach.

Deya Corzo, the Chief Medical Officer, -Residence at Roivant, provides critical clinical insights and strategic guidance for drug development programs. Corzo focuses on ensuring the scientific rigor and patient-centricity of Roivant's late-stage drug candidates. Overseeing clinical strategy, the Chief Medical Officer, -Residence guides the translation of promising research into effective patient treatments. This role involves evaluating medical data, advising on clinical trial design, and ensuring compliance with regulatory standards. By contributing deep medical expertise, Deya Corzo directly enhances Roivant's capacity to deliver innovative healthcare technologies that meet significant patient needs. Ultimately, Corzo champions the clinical success of the company's pipeline, reinforcing its commitment to patient well-being.